Summary
Eloralintide targets amylin, a different hormone pathway from GLP-1. This small trial provided an early weight-loss signal, not a verdict on long-term treatment.
Who took part
Researchers randomized 100 adults without diabetes to weekly eloralintide or placebo for 12 weeks. Most participants were men; 78 completed the study.
100 adults randomized; safety was the main question
Eloralintide
73 participants
Placebo
27 participants
Completed study
78 participants overall
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Eloralintide | 73 participants |
| Placebo | 27 participants |
| Completed study | 78 participants overall |
What readers should know
Higher-dose groups lost more weight than placebo. Nausea affected 6 of 73 eloralintide recipients and none of 27 placebo recipients.
Eleven eloralintide recipients and two placebo recipients left the study because of adverse events, including COVID-19. Four eloralintide recipients experienced mood-related events. Two participants had serious events judged unrelated to treatment; nobody died.
The study was small, short, and primarily designed to examine safety. It cannot establish that eloralintide is better tolerated than another medicine.
Lilly funded and conducted the research; all authors were employees and shareholders.
Before weekly treatment: the first single-dose study
A separate trial tested one injection in 48 healthy adults, followed for weight changes through day 29. All completed the study. The highest-dose group was an estimated average 4.4% below starting weight; each active group had only six people. Digestive symptoms occurred, but there were no serious adverse events or treatment discontinuations.
This was early safety research, not proof of durable weight management. The paper’s body-composition findings came from animals, not these participants. Lilly funded the study; its authors were employees and shareholders.
Sources
Bhattachar and colleagues, Diabetes, Obesity and Metabolism, 2026.